abaloparatide (Rx)

Brand and Other Names:Tymlos
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

solution for SC injection

  • 80mcg/40mcL (available as a prefilled pen that delivers 30 daily doses of 80mcg)

Osteoporosis

Indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy

In postmenopausal women with osteoporosis, clinical trials showed abaloparatide reduces the risk of vertebral fractures and nonvertebral fractures

80 mcg SC qDay

Cumulative use of abaloparatide and parathyroid hormone (PTH) analogs for >2 yr not recommended (see Dosing Considerations and Black Box Warnings)

Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate

Dosing Considerations

Limitations of use: Because of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of abaloparatide and PTH analogs (eg, teriparatide) for >2 yr during a patient’s lifetime is not recommended

Safety and efficacy not established

Next:

Adverse Effects

>10%

Injection site redness (58%)

Hypercalciuria (11%)

1-10%

Dizziness (10%)

Injection site edema (10%)

Nausea (8%)

Headache (8%)

Palpitations (5%)

Orthostatic hypotension (4%)

Fatigue (3%)

Upper abdominal pain (3%)

Hypercalcemia (3%)

Vertigo (2%)

Tachycardia (2%)

Previous
Next:

Warnings

Black Box Warnings

Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma (a malignant bone tumor) in male and female rats; this effect was observed at systemic exposures to abaloparatide ranging from 4-28 times the exposure in humans receiving the 80-mcg dose

It is unknown if abaloparatide causes osteosarcoma in humans

Use is not recommended in patients at increased risk of osteosarcoma, including those with Paget disease of bone or unexplained elevations of alkaline phosphatase, open epiphyses, bone metastases or skeletal malignancies, hereditary disorders predisposing to osteosarcoma, or prior external beam or implant radiation therapy involving the skeleton

Cumulative use of abaloparatide and PTH analogs (eg, teriparatide) for >2 yr during a patient’s lifetime is not recommended

Contraindications

None

Cautions

Dose-dependent increase in incidence of osteosarcoma in rats observed (see Black Box Warnings)

May cause orthostatic hypotension, typically within 4 hr after injection; instruct patient to sit or lie down for the first several doses if necessary

May cause hypercalcemia; not recommended with preexisting hypercalcemia or in patients who have an underlying hypercalcemic disorder (eg, primary hyperparathyroidism) because of the possibility of exacerbating hypercalcemia

May cause hypercalciuria; unknown whether the drug may exacerbate urolithiasis in patients with active or a history of urolithiasis; if active urolithiasis or preexisting hypercalciuria is suspected, measurement of urinary calcium excretion should be considered

Previous
Next:

Pregnancy

Pregnancy

Not indicated for females of reproductive potential

Lactation

Not indicated for females of reproductive potential

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Synthetic peptide analog of human parathyroid hormone-related protein (hPTHrP); hPTHrP is a naturally occurring hormone that, among other functions, regulates bone formation

Elicits anabolic effect on bone, demonstrated by increases in bone mineral density and content that correlated with increases in bone strength at vertebral and/or nonvertebral sites

Absorption

Absolute bioavailability: 36%

Peak plasma time: 0.51 hr

Peak plasma concentration: 312 pg/mL

AUC: 1622 pg·hr/mL

Distribution

Protein bound: 70%

Vd: ~50 L

Metabolism

No specific metabolism or excretion studies have been performed

Metabolism is consistent with nonspecific proteolytic degradation into smaller peptide fragments, followed by elimination by renal clearance

Elimination

Half-life: 1.7 hr

Excretion: Primarily in urine

Previous
Next:

Administration

SC Preparation

Clear and colorless solution

Visually inspect for particulate matter and discoloration prior to administration

Do not use if solid particles appear or if the solution is cloudy or colored

Provide appropriate training and instruction to patients and caregivers on the proper use of the pen

SC Administration

Administer as a SC injection into the periumbilical region of the abdomen

Rotate the site of the injection every day and administer at approximately the same time every day

Do not administer IV or IM

Administer the first several doses where the patient can sit or lie down if necessary, in case symptoms of orthostatic hypotension occur

Storage

Before first use: Refrigerate between 2-8°C (36-46°F)

After first use: Store for up to 30 days at 20-25°C (68-77°F)

Do not freeze or subject to heat

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.